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Effect of Formulation Variables on the Percutaneous
Permeation of Ketoprofen from Gel Formulations
Ayman F. El-Kattan, Charles S. Asbill, Nanhye Kim, and Bozena B. Michniak
Dept. of Basic Pharmaceutical Sciences College of Pharmacy,
University of South Carolina, Columbia, South Carolina, USA
The objectives of our study were to evaluate the effect of four
terpene enhancers, enhancer lipophilicity, and ethanol concentra-
tion using hydroxypropyl cellulose (HPC) and two Pluronic F-127
(PF-127) gel formulations on the percutaneous permeation of keto-
profen. All experiments were conducted using hairless mouse skin
in vitro. Data recorded over 24 hr was compared with that for
control gels (containing no terpene) using Franz diffusion cells. In
the three gel formulations, the highest increase in the ketoprofen
permeation was observed using limonene followed by nerolidol,
fenchone, and thymol. Relationships were established between ter-
pene lipophilicity, enhancement ratios for ketoprofen  ux (ER ux),
and the cumulative amount of ketoprofen after 24 hr (Q24 ) from
the three gel formulations. However, no correlation was established
between terpene lipophilicity and ketoprofen skin content values
at 24 hr. Ethanol had a synergistic effect on the enhancing activity
of the terpenes. Increasing the concentration of ethanol from 10%
to 50% was associated with an increase in the permeation of ke-
toprofen. For example, use of PF-127 gel control (no terpene was
included) containing 10% ethanol resulted in a ketoprofen  ux of
19 § 2 ¹g/cm2 h and 481 § 131 ¹g/cm2 for Q24. Furthermore, for
PF-127 containing 33% ethanol the  ux was 34 § 3 ¹g/cm2 h and
Q24 was 1420 § 111 ¹g/cm2. However, HPC gel control that con-
tained 50% ethanol resulted in a ketoprofen  ux of 67 § 6 ¹g/cm2 h
and 2839 § 222 ¹g/cm2 for Q24.
Keywords Flux, Hydroxypropy l Cellulose, Ketoprofen, Log P,
Pluronic F-127, Terpenes
Ketoprofen is a potent nonsteroidal anti-in ammatory drug
(NSAID) with antipyretic properties that is widely used for the
acute and long-term management of rheumatoid arthritis. How-
ever, the oral administration of this drug is usually accompanied
by severe gastric and duodenal irritation (Lanza et al. 1998) and
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because of its short half-life of 1.1–4 hr, it requires frequent oral
dosage. Transdermal administration of ketoprofen would be a
possible alternative offering distinct advantages, such as elimi-
nation of the variable rate of absorption and  rst-pass intestinal
and hepatic metabolism inherent with oral dosing. Furthermore,
this route provides sustained controlled drug administration at
a zero order rate similar to that provided by intravenous (IV)
infusion that is crucial for drugs with short half-lives. The trans-
dermal route overcomes the risks and inconvenience associated
with parenteral route use and eliminates many side effects from
reduction of the peaks in drug plasma levels. As a result, pa-
tient compliance is improved (Southwell and Barry 1983; Barry
1987; Goodman and Barry 1988; Williams and Barry 1992).
Ultimately, the success of all transdermal systems depends
on the ability of the drug to permeate the skin, in particular the
stratum corneum which is recognized as the predominant diffu-
sional barrier for drug permeation across the skin. To promote
drug permeation across the skin, chemical penetration enhancers
may be included in transdermal formulations. Many studies
have evaluated such enhancers and their mechanisms of activity
(Barry and Bennett 1987; Williams and Barry 1992; Aoyagi and
Nagase 1995; Ogiso et al. 1995; Godwin and Michniak 1999;
Kim et al. 1999).
Terpenes are natural volatile oils with low cutaneous irri-
tancy and are therefore good candidates as skin penetration en-
hancers (Opdyke 1979). Monoterpenes, in particular, are effec-
tive penetration enhancers for both hydrophilic and lipophilic
drugs (Okamoto et al. 1988; Godwin and Michniak 1999).
Enhancers and actives need to be placed in effective formula-
tion bases. Hydrogels are such vehicles for the transdermal de-
livery of drugs and include hydroxypropy l cellulose (HPC) and
Pluronics F-217 (PF-127). HPC is extensively used in oral
and topical pharmaceutical formulations owing to its nontoxic
and nonirritant properties (Wade and Weller 1995). In topical
formulations, it is used as a thickening and viscosity-increasing
agent, stabilizer, and emulsifying agent (Machida and Nagai
1974; Johnson et al. 1993). PF-127 is a nonionic surface ac-
tive polyoxyethylene-polyoxypropylen e copolymer that is used
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primarily in pharmaceutical formulations as an emulsifying and
solubilizing agent (Collett et al. 1979; Collett and Tobin 1979;
El Shaboury 1989). It is reported to be nonirritant and nontoxic
(Miyazakin et al. 1986; Gill et al. 1994). Unlike HPC, PF-127
has a sol-gel transition in the 25–35±C temperature range, re-
sulting in thermogels (Saettone et al. 1988).
The objectives of our study were threefold: to evaluate the ef-
fect of terpene enhancers on the permeation of ketoprofen from
gel formulations; to establish relationships between the terpene
lipophilicity (fenchone log P 2.1 § 0.3, thymol log P 3.28 § 0.3,
limonene log P 4.6 § 0.2, and nerolidol log P 5.4 § 0.4) and the
various ketoprofen percutaneous parameters from the three gel
formulations; and to investigate the effect of ethanol concentra-
tions in the gel formulations on the permeation of ketoprofen
across hairless mouse skin in vitro.
METHODS
Materials
Ketoprofen was provided by Sigma Chemical Co. (St. Louis,
MO). Acetonitrile, methanol, and water used in the HPLC
procedures were of analytical grade and purchased from EM
Science (New Briggs, NJ). Aaper Alcohol and Chemical Co.
(Shelbyville, KY) supplied the ethanol USP. Fenchone, thymol,
d-limonene, and nerolidolwere obtained fromAldrich Chemical
Company (Milwaukee, WI). Glycerol, PF-127, and HPC were
purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA).
Female hairless mice strain SKH1 (hr/hr), 6–8 weeks old were
obtained from Charles River Lab. (Wilmington, MA). All used
chemicals were without further puri cation.
Preparation of Gel Formulations
HPC gels were prepared using the recently reported method
described by El-Kattan et al. (2000). The HPC gel composition
is shown in Table 1. Brie y, ethanol was mixed with glycerol
and distilled water. Then HPC was added slowly with contin-
uous mixing until gel was formed. Then ketoprofen followed
by terpene were added to the gel and mixed. The gels were left
overnight at ambient temperature in a tightly sealed container.
TABLE 1
Composition (%w/w) of ketoprofen HPC gel
Component % w/w
Ketoprofen 10
Ethanol 50
Water 26
Glycerol 10
Terpene 2
HPC 2
TABLE 2
Composition (% w/w) of PF-127 gels
Gel A Gel B
Component % w/w % w/w
PF-127 20 20
Puri ed water 80 50
Ethanol — 30
Two PF-127 gels were prepared using the method described
by Schmolka (1972). Gel A and Gel B compositions are shown
in Table 2. For the preparation of Gel A, a weighed amount of
PF-127 powder wasmixed into cold waterwith agitation. For the
preparation of Gel B, 30% alcohol solution was used instead of
puri ed water. The mixture, following storage for 24 hr at 4±C,
became a transparent solution. For the preparation of Gels C
and D containing 10% ketoprofen, a mixture of 10% ketopro-
fen, 10% alcohol, and 2% terpene was prepared and thoroughly
mixed in 78% PF-127 (using Gels A and B) in an ice-water bath
and the solutions formed Gel C and D, respectively, at room
temperature (Table 3).
In Vitro Skin Permeability Studies
Skin permeation of ketoprofen from gel formulations was
measured using Franz diffusion cells (Permegear Inc.,
Riegelsville, PA). The effective permeation area of the diffu-
sion cell and receptor cell volume were 0.64 cm2 and 5.1 ml,
respectively. The temperature was maintained at 37 § 0.5±C.
The receptor compartment contained isotonic phosphate buffer
(pH 7.2) and 0.1% formaldehyde (37%) as a preservative and
was constantly stirred at 600 rpm. Female hairless mouse skin
(SKH1, Charles River Lab.) was mounted between the donor
and receptor compartments. The 10% ketoprofen gel formula-
tion (300 mg) was applied under occlusion to the epidermal
surface of the mouse skin. A portion of the receptor solution
(300 l l) was collected through the sampling port of the diffu-
sion cell at predetermined time intervals over 24 hr. The receptor
phase was immediately replenished with equal volume of fresh
diffusion buffer. Samples were frozen at ¡ 70±C before HPLC
TABLE 3
Composition (% w/w) of ketoprofen PF-127 gels
Gel C Gel D
Component % w/w % w/w
Ketoprofen 10 10
Ethanol 10 10
Terpene 2 2
Gel A 78 —
Gel B — 78
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analysis. After 24 hr, the skins were removed from the cells and
washedbrie y inmethanol using previously reportedprocedures
(Michniak et al. 1994). The skins were then homogenized in 4ml
methanol using a Kinematica GmbH tissue homogenizer. The
homogenates were  ltered and stored at ¡ 70±C until analyzed
using HPLC (Michniak et al. 1993).
HPLC Analysis of Ketoprofen
The liquid chromatograph used (Hewlett Packard 1100
HPLC) was equipped with a quaternary pump with a variable–
wavelength detector operating at 242 nm and an autosampler
with an injection volume of 20 l l. Analysis was performed at
ambient temperature on a C18 -Microsorb column (15 cm £ 4.6
mm and 5 l m diameter). The mobile phase consisting of ace-
tonitrile: 60 mM KH2PO4: triethanolamine (49:51:0.05), was
pumped at a  ow rate of 1 m/1 min. Calibrations were carried
out by the external standard methods.
Data Analysis
In vitro percutaneous permeation parameters were calculated
using equation 1.
Jt = (1/ A)(dM/dt) [1]
where Jt is the  ux ( l g/cm2 hr), dM/dt is the slope of the cumu-
lative corrected drug amount in the receptor compartment versus
time, and A is the diffusional area (cm2).
The steady-state  ux, Jt ( l g/cm2 hr)was determined from the
slope of the linear portion of the cumulative amount permeated
per unit area versus time plot. The lag time was determined
by extrapolating the linear portion of the curve to the abscissa.
Log P values of terpene enhancers were determined using ACD
software program (Advanced Chemistry Incorporated, Ontario,
Canada). Enhancement ratios for  ux (ER ux) were calculated
using the following equation:
ER ux =
Ketoprofen  ux with enhancer in gel
Ketoprofen  ux without enhancer in gel (control)
[2]
The data are presented as means § SD of  ve experiments.
Statistical analyses were performed using one-way ANOVA.
Correlation analyses were performed by the least squares linear
regression method.
RESULTS
Effect of HPC Formulations on the Percutaneous
Permeation of Ketoprofen
The effect of terpene enhancers on the percutaneous perme-
ation pro les of ketoprofen is depicted in Figure 1. The  ux,
ER ux , cumulative amount of ketoprofen after 24 hr (Q24 ), and
ketoprofen skin content (SC) are shown inTable 4. Controls con-
sisted of gel formulations with no terpene incorporation and the
FIG. 1. The permeation pro le for ketoprofen from the HPC gel systemusing
terpene enhancers . Means § SE, n = 5.
 ux recordedwas 67§6 l g/cm2 hr, Q24 was 2839§222 l g/cm2,
and 9384 § 1789 l g/g for SC. Terpene enhancers had a sig-
ni cant effect on the percutaneous permeation parameters of
ketoprofen across the female hairless mouse skin in relation to
control (p < .05) (Table 4). ER ux using limonene (4.5) was not
signi cantly different from that for nerolidol (4.4) and fenchone
(3.7) (p > .05); however, it was signi cantly higher than that
observed with thymol (3.1) (p < .005) and control (p < .001).
The use of limonene resulted in the highest increase in Q24
(6473 § 539 l g/cm2) that was signi cantly higher than con-
trol (p < .0005). However, it was not signi cantly different
from nerolidol (5887 § 1120 l g/cm2) and fenchone (5416 §
1042 l g/cm2) (p > .05). Thymol provided the lowest increase
in Q24 (4649 § 574 l g/cm2), yet it was signi cantly higher than
that provided by control gel (p < .01).
The highest ketoprofen skin content was observed with fen-
chone (16926 § 578 l g/g) followed by limonene (14086 §
934 l g/g), thymol (13539 § 5443 l g/g), and nerolidol (11184 §
2557 l g/g).
TABLE 4
Effect of terpenes on ketoprofen percutaneous permeation
from HPC ketoprofen gel (n = 5) (means § SD)
Flux
Enhancer ( l g/cm2 hr) ER ux Q24 ( l g/cm2) SC ( l g/g)
Control 67 § 6 1.0 2839 § 222 9384 § 1789
Fenchone 248 § 39 3.7 5416 § 1042 16926 § 578
Thymol 207 § 23 3.1 4649 § 574 13539 § 5443
Limonene 304 § 14 4.5 6473 § 539 14086 § 934
Nerolidol 297 § 23 4.4 5887 § 1120 11184 § 2557
SC: skin content of ketoprofen after 24 hr; Q24: cumulative amount
of ketoprofen in the receptor after 24 hr; ER ux: enhancement ratio of
ketoprofen  ux.
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TABLE 5
Effect of terpenes on ketoprofen percutaneous permeation
from ketoprofen PF-127 Gel C (n = 5) (means § SD)
Flux
Enhancer (l g/cm2 hr) ER ux Q24 ( l g/cm2) SC (l g/g)
Control 19 § 2 1.0 481 § 131 11424 § 3015
Fenchone 84 § 11 4.4 1770 § 243 6512 § 1551
Thymol 66 § 17 2.9 1441 § 189 7158 § 727
Limonene 121 § 16 6.2 2592 § 508 5670 § 2534
Nerolidol 104 § 22 5.5 2289 § 622 12804 § 2692
SC: skin content of ketoprofen after 24 hr; Q24: cumulative amount
of ketoprofen in the receptor after 24 hr; ER ux: enhancement ratio of
ketoprofen  ux.
Effect of Pluronic Acid Gel Formulations on the
Percutaneous Permeation of Ketoprofen
Two PF-127 gel formulations were prepared with different
ethanol contents (Gels C and D, Table 3). The effect of ter-
pene enhancers on the percutaneous permeation parameters of
ketoprofen using Gels C and D is shown in Tables 5 and 6,
respectively. Similar to the data obtained with HPC gel formu-
lations, the terpenes had a pronounced effect on the percutaneous
permeation parameters of ketoprofen (Figures 2 and 3).
In GelC , limonene showed the best enhancing effect in terms
of ketoprofen ER ux (6.2), which was signi cantly higher than
control (p < .001). However, it was not signi cantly different
from the ER ux provided by nerolidol (5.5) and fenchone (4.4)
(p > .05). Thymol provided the lowest increase in the ER ux
(2.9), whichwas signi cantly lower than limonene (p < .05)yet
higher than control (p < .05). In addition to providing the high-
est ER ux , limoneneprovided the highest increase inQ24 (2592§
508 l g/cm2) in relation to control (481§131 l g/cm2) (p < .01).
Nerolidol and fenchone increasedQ24 to 2289§ 622 l g/cm2 and
1770 § 243 l g/cm2, respectively. However, they were not sig-
ni cantly different from limonene (p > .05). The lowest Q24
was provided by thymol (1441 § 189 l g/cm2). The highest ke-
TABLE 6
Effect of terpenes on ketoprofen percutaneous permeation
from ketoprofen PF-127 Gel D (n = 5) (means § SD)
Flux
Enhancer (l g/cm2 hr) ER ux Q24 ( l g/cm2) SC (l g/g)
Control 34 § 3 1.0 1420 § 111 9850 § 3300
Fenchone 141 § 53 4.1 3228 § 1191 13812 § 3147
Thymol 110 § 19 3.2 2717 § 215 13586 § 2531
Limonene 256 § 23 7.5 5932 § 434 5932 § 434
Nerolidol 242 § 28 7.1 4956 § 373 13875 § 4632
SC: skin content of ketoprofen after 24 hr; Q24: cumulative amount
of ketoprofen in the receptor after 24 hr; ER ux: enhancement ratio of
ketoprofen  ux.
FIG. 2. The permeation pro le for ketoprofen from the PF-127 Gel C system
using terpene enhancers . Means § SE, n = 5.
toprofen skin content was observed with nerolidol (12804 §
2692 l g/g) which was not signi cantly higher than the con-
trol gel (11424 § 3015 l g/g) (p > .05). Thymol, fenchone, and
limonene provided ketoprofen skin contents (7158 § 727 l g/g,
6512 § 1551 l g/g, and 5670 § 2534 l g/g, respectively) that
were not signi cantly lower than control (p < .05).
In Gel D, limonene also provided the best enhancing ac-
tivity in terms of ketoprofen ER ux (7.5), which was signi -
cantly higher than control (p < .0001). However, it was not sig-
ni cantly different than the ER ux provided by nerolidol (7.1)
(p > .05). Fenchone and thymolprovided 4.1 and3.2 increase in
ER ux which were signi cantly lower than limonene (p < .025)
and (p < .001), respectively, yet higher than control (p < .002)
and (p < .0001), respectively. Similar to the results obtained
with HPC gel and Gel D, limonene provided the highest in-
crease in Q24 (5932 § 434 l g/cm2) compared with control
FIG. 3. The permeation pro le for ketoprofen from the PF-127 Gel D system
using terpene enhancers . Means § SE, n = 5.
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(1420 § 111 l g/cm2) (p < .00025). Nerolidol increased Q24
to 4956 § 373 l g/cm2; however, it was not signi cantly dif-
ferent from limonene (p > .05). Fenchone increased Q24 to
3228 § 1191 l g/cm2 that was signi cantly lower than limonene
(p > .01). Thymol provided the lowest increase in Q24 (2717 §
215 l g/cm2) relative to control gel. The highest ketoprofen skin
content was observed with nerolidol (13875 § 4632 l g/g), fol-
lowed by thymol (13586 § 2531 l g/g), and fenchone (13812 §
3147 l g/g). They were not signi cantly higher than control
(9850 § 3300 l g/g) (p > .05). The lowest ketoprofen skin
content was provided by limonene (5932 § 434 l g/g), and it
was not signi cantly lower than control (p > .05).
DISCUSSION
In our study, the effect of four terpene enhancers (fenchone,
thymol, limonene, and nerolidol) on the percutaneous perme-
ation of ketoprofen was evaluated from three gel formulations
using hairless mouse skin in vitro. Hairless mouse skin was used
as a model skin although it does provide higher permeability
than human skin. The basic mechanism of permeation, how-
ever, is thought to be similar between the two species (Ghosh
and Bagherian 1996; Gorukanti et al. 1999). A number of re-
search groups independently investigated the mechanism of ter-
pene permeation enhancement activity using differential scan-
ning calorimetry and Fourier transform infrared (Cornwell and
Barry 1991, 1994; Zhao and Singh 1999). They found that ter-
penes increased the drug percutaneous permeation mainly by
disrupting the highly ordered intercellular packing of the stra-
tum corneum lipids.
Terpene enhancers had a signi cant effect on the percuta-
neous permeation of ketoprofen from the evaluated gel for-
mulations. Furthermore, the results suggested that limonene, a
hydrocarbon terpene, was more effective in promoting the per-
cutaneous permeation of ketoprofen (lipophilic drug with a logP
of 2.81§ 0.33) from the gels, when compared with that provided
by polar terpenes such as thymol, fenchone, and nerolidol. The
data obtained were similar to those reported by other research
groups (Koyama et al. 1994; Ogiso et al. 1995; Moghimi et al.
1998; Godwin and Michniak 1999; Kitagawa and Li 1999).
Koyama and coworkers (1994) investigated the enhancing ef-
fect of limonene on the percutaneous permeation of mannitol
(hydrophilic drug), 6-mercaptopurine (amphiphilic drug), and
butylparaben (lipophilic drug) using guinea pig skin in vitro.
They reported that limonene had a signi cant effect on the per-
cutaneous permeation of butylparaben and 6-mercaptopurine
but had a little effect on the mannitol percutaneous permeation
(Koyama et al. 1994). They attributed the enhancing activity
of limonene to its ability to increase drug diffusivity by dis-
rupting the normal packing of the skin. Furthermore, limonene
decreased lipophilic drug partitioning in the nonpolar route lead-
ing to an acceleration of its penetration. Yamane et al. (1995)
evaluated the effect of 1,8 cineole, menthone, nerolidol, and
limonene in propyleneglycol/water on the permeationof amodel
hydrophilic permeant, 5- uorouracil, using excised human skin
in vitro. 1,8 cineole, menthone, and nerolidol increased the per-
meation of 5- uorouracil signi cantly through disrupting the
lipid packing of the stratum corneum or by increasing the drug
partitioning. However, limonene did not signi cantly increase
5- uorouracil permeation.
In our study, nerolidol was the most effective penetration
enhancer compared with fenchone and thymol. Its high enhanc-
ing activity has been previously reported and is attributed to
its amphiphile-like structure that may lead to the disruption of
the lipid packing of the stratum corneum (Cornwell and Barry
1994a, 1994b; Yamane et al. 1995).
It is interesting to note that the increase in the lipophilicity
of the terpene was associated with a proportional increase in the
percutaneous permeation of ketoprofen. The correlation coef -
cient between the lipophilicity of terpene and ER ux was 0.736
in HPC gel, 0.652 in PF-127 Gel C , and 0.82 in PF-127 Gel
D. Furthermore, the correlation coef cient between the log P of
terpene enhancers and Q24 was 0.60 inHPC gel, 0.706 in PF-127
Gel C , and 0.76 in PF Gel D. No correlation was established
between the log P of the terpene enhancers and the ketoprofen
skin contents using the three gel formulations. Similar results
were reported by El-Kattan et al. (2000). A correlation coef -
cient was established between the terpene log P and the  ux of
hydrocortisone, and log P and cumulative amount of hydrocorti -
sone after 24 hr (0.891 and 0.772, respectively). No correlation
was found between the log P of terpene and hydrocortisone skin
content.
In our present study, the formulations containing HPC pro-
vided the highest increase in the percutaneous permeation of
ketoprofen relative to the PF-127 formulations. This effect may
be attributed to the higher ethanol concentration found in the
HPC formulations (Table 1). Decreasing the concentration of
ethanol from 50% to 33% and to 10% when using HPC gel, PF-
127 Gel D and C , respectively, was associated with a decrease
in the ketoprofen percutaneous permeation. The synergistic ef-
fect of ethanol on the enhancing activity of terpene enhancers
was evaluated previously (Kikuchi et al. 1992; Priborsky et al.
1992; Maitani et al. 1996; Zhao and Singh 1999). Okabe et al.
evaluated the effect of limonene and ethanol on the percuta-
neous permeation of ketoprofen from acrylic gel patches using
rat skin in vivo.They demonstrated that limonene did not provide
any enhancing activity for ketoprofen permeation when ethanol
was not used. Furthermore, when ethanol was combined with
limonene and a hydrophilic acrylic polymer, the permeability of
ketoprofen was increased signi cantly suggesting that ethanol
is an essential adjuvant to obtain the activity of d-limonene. We
reported earlier the effect of ethanol and glycerol concentra-
tions on the percutaneous permeation of hydrocortisone from
HPC gel formulations (El-Kattan et al. 1999). We showed that
increasing ethanol concentration from 0% to 56% to 85% was
associated with a signi cant increase in the permeation of hy-
drocortisone. On the other hand, glycerol concentrations did
not have a signi cant effect on the percutaneous permeation of
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hydrocortisone at a concentration range of 0–10%. At 35% glyc-
erol, the permeation of hydrocortisone decreased signi cantly
and was attributed to the hygroscopic properties of glycerol at
high concentrations. Kobayashi et al. (1994) reported that the
simultaneous use of menthol and ethanol affected the inherent
enhancing activity of the two enhancers. In addition, they sug-
gested that the enhancing effect was synergistic. However, the
mechanisms of enhancement of both enhancers were different,
with ethanol providing enhancing activity by increasing porosity
of the stratumcorneum andmenthol by promoting drug diffusion
through disrupting the lipid backing of the skin.
CONCLUSION
Terpene enhancers had a signi cant effect on the percuta-
neous permeation of ketoprofen from gel formulations. Limon-
ene showed the highest enhancement of ketoprofen permeation
compared with other terpene enhancers and control followed
by nerolidol, fenchone, and thymol. The increase in terpene en-
hancer lipophilicity was associated with a proportional increase
in the ER ux and Q24 . No correlation was established between
terpene lipophilicity and ketoprofen skin contents provided by
the three formulations. Ethanol is an important adjuvant for the
proper enhancing activity of the terpene enhancers and increas-
ing its concentration was associated with an increase in perme-
ation of ketoprofen across the skin.
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